|
| |
National Cancer CentreWelcome to the website for National Cancer Centre, Singapore (NCC). As a national and regional centre of excellence, we are committed to excellence in research, education and clinical services.At NCC, we adopt a multidisciplinary and holistic approach to cancer treatment. We undertake training and education of medical, radiation and surgical oncologists and other allied health personnel to develop relevant clinical and basic research programmes in the understanding, prevention, diagnosis and treatment of cancer.We strive to provide the highest standards of medical diagnosis, treatment and patient care.This website provides you with general information about our specialist oncology clinics and other outpatient services which we provide. We welcome any feedback and suggestions you may have in improving our website in order to serve your needs better.
| Contact Details: |
| 11 Hospital Drive |
| |
| |
| 169610 |
| Singapore |
| Tel: | 65 6436 8000 |
| Fax: | 65 6225 6283 |
| Email: | corporate@nccs.com |
| WWW: | www.nccs.com.sg/
|
| |
Recent Publications by National Cancer Centre: |  |
Telomere shortening relaxes X chromosome inactivation and forces global transcriptome alterations.
Telomeres are heterochromatic structures at chromosome ends essential for... | 6th November, 2009
| Telomeres and Telomerase Group, Molecular Oncology Program, Spanish
| Proc Natl Acad Sci U S A. 2009 Nov 3.
DOI Direct Link |
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.
Asia has a disproportionately large share of the world's hepatocellular... | 3rd November, 2009
| National Cancer Centre, Singapore; Duke-NUS Graduate Medical School,
| Lancet Oncol. 2009 Nov;10(11):1111-8.
DOI Direct Link |
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009.
The addition of a planned neck dissection after radiotherapy has... | 3rd November, 2009
| National
| Lancet Oncol. 2009 Nov;10(11):1086-92.
DOI Direct Link |
Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
Patients with breast cancer positive for human epidermal growth-factor... | 3rd November, 2009
| Department of Medical Oncology, National Cancer Centre, Singapore.
| Lancet Oncol. 2009 Nov;10(11):1077-85.
DOI Direct Link |
Pragmatic classification of superficial neoplastic colorectal lesions.
Patients with breast cancer positive for human epidermal growth-factor... | 3rd November, 2009
| Current affiliations: Screening Group (R.L.), International Agency for
| Gastrointest Endosc. 2009 Oct 29.
DOI Direct Link |
→View more National Cancer Centre research publications. |
Press Releases on National Cancer Centre:
|
 |
| YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS |
11th November, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, Nov. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
|
| YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 |
2nd November, 2009 |
YM BioSciences Inc. |
- Follow-On Results from a Randomized Phase IIb Head & Neck Trial
Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated
Toxicities -
MISSISSAUGA, ON, Nov. 2
|
| Pharma and Biotech Companies Plug into Singapore's Integrated Research Network |
19th May, 2009 |
|
ATLANTA, May 19 /PRNewswire/ -- Leading pharmaceutical and biotech companies are drawing on Singapore's
integrated network of public-sector and academic institutes to enhance their
R&D
|
| YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS |
14th May, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, May 14 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of
|
| YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER |
5th January, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 111 individuals from National Cancer Centre using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 275 times since April 2007, the link to the organisation's website has been followed 39 times Recent Search Terms used to find this page: polyvinyl pyrrolidone | . This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for National Cancer Centre |
